A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Eric Reiman, M.D.
Banner Alzheimer's Institute
Principal Investigator - Jessica Langbaum, Ph.D.
Banner Alzheimer's Institute
Principal Investigator - Robert Alexander, M.D.
Banner Alzheimer's Institute
Principal Investigator - Yakeel T. Quiroz-Gaviria, Ph.D.
Massachusetts General Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Neurosciences Group of Antioquia, University of Antioquia
Medellín, Antioquia, Colombia
David F Aguillon Nino, M.D.
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Jan 2026
- Primary completion
- 1 Jun 2030
- Completion
- 1 Jun 2030
- Last update posted
- 3 Aug 2025
- Registered enrollment
- 240
- Registry id
- NCT06996730
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.